Oncology and Hematology: Archives

SUMMARY AND COMMENT

Prostate Cancer Screening: Still No Mortality Benefit

• February 7, 2012
• Robert Dreicer, MD, MS, FACP

Results after 13 years of follow-up in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial confirmed earlier findings.

• Reviewing:
• Andriole GL et al., J Natl Cancer Inst 2012 Jan 18; 104:125

SUMMARY AND COMMENT

Marrow Fibrosis at Diagnosis Affects Outcome of Polycythemia Vera

• February 7, 2012
• David Green, MD, PhD

PV patients with fibrosis were less likely than those without fibrosis to develop thrombosis but more likely to have splenomegaly and develop myelofibrosis.

• Reviewing:
• Barbui T et al., Blood 2012 Jan 13

SUMMARY AND COMMENT

Preventing Catheter Thrombosis During Percutaneous Coronary Interventions

• February 7, 2012
• David Green, MD, PhD

Heparin was more effective than fondaparinux at inhibiting clotting induced by the contact activation pathway.

• Reviewing:
• Yau JW et al., Blood 2011 Dec 15; 118:6667

SUMMARY AND COMMENT

Thigh-Length vs. Below-Knee Compression Stockings

• January 31, 2012
• David Green, MD, PhD

Prevention of postthrombotic syndrome was similar with both types of stockings in patients with venous thrombosis, but adverse effects were less common with below-knee stockings.

• Reviewing:
• Prandoni P et al., Blood 2011 Dec 16

SUMMARY AND COMMENT

Early-Stage Hodgkin Lymphoma: New Lessons from an Old Study

• January 31, 2012
• Michael E. Williams, MD

Overall survival was improved for patients treated with ABVD chemotherapy versus subtotal nodal irradiation.

• Reviewing:
• Meyer RM et al., N Engl J Med 2011 Dec 11 Straus DJ., N Engl J Med 2011 Dec 11

MEETING REPORT

Report from the 53rd American Society of Hematology Annual Meeting and Exposition — Part 2: Malignant HematologyFree

• January 31, 2012
• Michael E. Williams, MD

The latest research in hematologic malignancies

SUMMARY AND COMMENT

Bevacizumab for Breast Cancer: What's Next?

• January 25, 2012
• William J. Gradishar, MD

Adding bevacizumab to neoadjuvant chemotherapy raised pathologic complete response rates, but questions remain.

• Reviewing:
• von Minckwitz G et al., N Engl J Med 2012 Jan 26; 366:299 Bear HD et al., N Engl J Med 2012 Jan 26; 366:310 Montero AJ and Vogel C., N Engl J Med 2012 Jan 26; 366:374

SUMMARY AND COMMENT

Adjuvant Radiation Therapy for Breast Cancer Affects Coronary Arteries

• January 24, 2012
• William J. Gradishar, MD

Stenosis occurred in certain regions of the arterial tree, but contemporary RT has evolved to minimize this risk.

• Reviewing:
• Nilsson G et al., J Clin Oncol 2011 Dec 27 Zagar TM and Marks LB., J Clin Oncol 2011 Dec 27

SUMMARY AND COMMENT

Dual Antibodies Reap Benefits Against HER2-Positive Metastatic Breast Cancer

• January 24, 2012
• William J. Gradishar, MD

Adding pertuzumab to trastuzumab plus docetaxel prolonged progression-free survival without raising risk for cardiac events.

• Reviewing:
• Baselga J et al., N Engl J Med 2012 Jan 12; 366:109

MEETING REPORT

The 2011 San Antonio Breast Cancer SymposiumFree

• January 24, 2012
• William J. Gradishar, MD

Highlights include adjuvant bisphosphonates, endocrine therapy, treatment of HER2-positive breast cancer, and genomic scores for predicting risk for recurrence of ductal carcinoma in situ.